Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma

Kinoshita,Hiroki; Okabe,Hirohisa; Beppu,Toru; Chikamoto,Akira; Hayashi,Hiromitsu; Imai,Katsunori; Mima,Kosuke; Nakagawa,Shigeki; Ishimoto,Takatsugu; Miyake,Keisuke; Yokoyama,Naomi; Ishiko,Takatoshi; Baba,Hideo

doi:10.3892/or.2012.2162

Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma

Authors:
- Hiroki Kinoshita
- Hirohisa Okabe
- Toru Beppu
- Akira Chikamoto
- Hiromitsu Hayashi
- Katsunori Imai
- Kosuke Mima
- Shigeki Nakagawa
- Takatsugu Ishimoto
- Keisuke Miyake
- Naomi Yokoyama
- Takatoshi Ishiko
- Hideo Baba
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
Published online on: November 30, 2012 https://doi.org/10.3892/or.2012.2162
Pages: 685-689

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cystine/glutamic acid transporter (xCT) plays a role in tumor progression by regulating the redox status in several types of cancers. To demonstrate the importance of xCT expression for predicting the prognosis of hepatocellular carcinoma (HCC), we analyzed xCT gene expression in 130 paired HCC and non-cancerous tissues. xCT protein expression was confirmed using 7 HCC cell lines and samples from human subjects. xCT mRNA expression was detected in 34 (26%) tumor tissues. Expression of xCT was higher in HCC tissues compared to the corresponding normal tissues according to quantitative reverse transcriptase-polymerase chain reaction findings (P<0.0001). Patients in the group presenting with xCT mRNA expression showed poorer overall and disease-free survival than did those with an absence of xCT mRNA (P=0.0130 and 0.0416, respectively). xCT mRNA expression proved to be an independent factor for poor prognosis in a multivariate analysis of overall survival (hazard ratio, 1.68; 95% CI, 1.03-2.92). We observed xCT protein expression in both the HCC cell lines and in human tissue samples. In conclusion, the findings of the present study suggest that xCT is useful as a predictive marker for patient prognosis and that it may be a novel therapeutic target for HCC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin. 62:10–29. 2012.
2	Carr BI: Hepatocellular carcinoma: current management and future trends. Gastroenterology. 127(Suppl 1): S218–S224. 2004. View Article : Google Scholar : PubMed/NCBI
3	Kassahun WT, Fangmann J, Harms J, et al: Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Exp Clin Transplant. 4:549–558. 2006.PubMed/NCBI
4	Griffith OW: Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med. 27:922–935. 1999. View Article : Google Scholar : PubMed/NCBI
5	Chung WJ, Lyons SA, Nelson GM, et al: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 25:7101–7110. 2005. View Article : Google Scholar : PubMed/NCBI
6	Doxsee DW, Gout PW, Kurita T, et al: Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 67:162–171. 2007. View Article : Google Scholar : PubMed/NCBI
7	Gout PW, Kang YJ, Buckley DJ, et al: Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia. 11:1329–1337. 1997. View Article : Google Scholar : PubMed/NCBI
8	Bannai S and Tateishi N: Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol. 89:1–8. 1986. View Article : Google Scholar : PubMed/NCBI
9	Verrey F, Closs EI, Wagner CA, et al: CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 447:532–542. 2004. View Article : Google Scholar : PubMed/NCBI
10	Lo M, Wang YZ and Gout PW: The x_c^- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 215:593–602. 2008.
11	Lyons SA, Chung WJ, Weaver AK, et al: Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 67:9463–9471. 2007. View Article : Google Scholar : PubMed/NCBI
12	Ishimoto T, Nagano O, Yae T, et al: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system x_c^- and thereby promotes tumor growth. Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
13	Okabe H, Beppu T, Ueda M, et al: Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. Int J Cancer. February 15–2012.(Epub ahead of print).
14	Fu LY, Jia HL, Dong QZ, et al: Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognoses. BMC Cancer. 9:492009. View Article : Google Scholar : PubMed/NCBI
15	Guo W, Zhao Y, Zhang Z, et al: Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett. 312:55–61. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lastro M, Kourtidis A, Farley K and Conklin DS: xCT expression reduces the early cell cycle requirement for calcium signaling. Cell Signal. 20:390–399. 2008. View Article : Google Scholar : PubMed/NCBI
17	Huang Y, Dai Z, Barbacioru C and Sadee W: Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 65:7446–7454. 2005. View Article : Google Scholar : PubMed/NCBI
18	Okuno S, Sato H, Kuriyama-Matsumura K, et al: Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer. 88:951–956. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bannai S: Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J Biol Chem. 261:2256–2263. 1986.PubMed/NCBI
20	Eck HP and Droge W: Influence of the extracellular glutamate concentration on the intracellular cyst(e)ine concentration in macrophages and on the capacity to release cysteine. Biol Chem Hoppe Seyler. 370:109–113. 1989. View Article : Google Scholar : PubMed/NCBI
21	Rimaniol AC, Mialocq P, Clayette P, et al: Role of glutamate transporters in the regulation of glutathione levels in human macrophages. Am J Physiol Cell Physiol. 281:C1964–C1970. 2001.PubMed/NCBI
22	Ganapathy V, Thangaraju M and Prasad PD: Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 121:29–40. 2009. View Article : Google Scholar : PubMed/NCBI
23	Capell HA, Madhok R, Porter DR, et al: Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis. 66:235–241. 2007. View Article : Google Scholar
24	Gout PW, Buckley AR, Simms CR and Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. Leukemia. 15:1633–1640. 2001. View Article : Google Scholar : PubMed/NCBI
25	Narang VS, Pauletti GM, Gout PW, et al: Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of doxorubicin. Chemotherapy. 53:210–217. 2007. View Article : Google Scholar